Abivax SA reports results for the quarter ended December 31 - Earnings Summary

• Abivax SA ABVX.OQ reported a quarterly adjusted loss of €1.14​​ per share for the quarter ended December 31. The mean expectation of five analysts for the quarter was for a loss of €1.28 per share. Wall Street expected results to range from €-1.90 to -90 cents per share.

• Revenue was €440.00 thousand​; analysts expected €1.44 million.

• Abivax SA's reported EPS for the quarter was a loss of €1.14​.

• The company reported a quarterly loss of €76.11 million.

• Abivax SA shares had fallen by 10.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Abivax SA is $146.50, about 21.2% above its last closing price of $115.42

This summary was machine generated from LSEG data March 24 at 03:14 a.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)